c-Met在肝细胞癌发生发展中的作用

王长青; 郭薇薇; 刘政

doi:10.3969/j.issn.1001-5256.2015.06.038

c-Met在肝细胞癌发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2015.06.038

1. 南京医科大学第二临床医学院
2. 南京医科大学第二附属医院消化医学中心

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2051
- HTML全文浏览量: 13
- PDF下载量: 488
- 被引次数: 0
出版历程
- 出版日期: 2015-06-20

Research progress in c-Met and hepatocellular carcinoma

摘要

摘要: c-Met在肝细胞癌的发生、发展中起着关键作用,可导致肿瘤细胞的增殖、存活、细胞骨架重组、分离扩散及血管生成等,同时还是评价预后的一个重要指标。c-Met在肝细胞癌中主要通过激活一系列信号通路发挥作用。近年来提出的小分子激酶抑制剂可阻止c-Met胞内羧基末端磷酸化,进而阻止信号转换器的募集及下游信号通路的传导,从而发挥抗肿瘤作用。基于对cMet的了解及其在肝细胞癌中的致癌作用,指出了选择性c-Met抑制剂靶向治疗肝细胞癌的应用前景。
- 癌,肝细胞 /
- 原癌基因蛋白质c-met /
- 信号传导 /
- 综述
Abstract: c- Met plays a pivotal role in the development and progression of hepatocellular carcinoma( HCC),which can lead to proliferation,survival,cytoskeleton reorganization,separation and diffusion,and angiogenesis of tumor cells. Moreover,c- Met is an important prognostic factor for HCC. In HCC,c- Met acts as an activator of a series of signaling pathways,including PI3 K / AKT / m TOR,ERK /MAPK,and Rac- Pak. In recent years,it has been reported that small- molecule kinase inhibitors can abolish phosphorylation at the intracellular carboxyl terminal of c- Met,and then inhibit the recruitment of signal convertors and downstream signaling pathways,which finally achieve anti- tumor activities. Based on the carcinogenic activity of c- Met in HCC,this paper points out that selective inhibitors of c- Met hold promise for targeted therapies for HCC.
- carcinoma,hepatocellular /
- proto-oncogene proteins c-met /
- signal transduction /
- review

HTML全文

参考文献(34)

[1]BOSETTI C,TURATI F,La VECCHIA C.Hepatocellular carcinoma epidemiology[J].Best Pract Res Clin Gastroenterol,2014,28(5):753-770.

[2]SHEN Q,FAN J,YANG XR,et al.Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma:a largescale,multicentre study[J].Lancet Oncol,2012,13(8):817-826.

[3]FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):e359-e386.

[4]LI J,HUANG L,LIU CF,et al.Risk factors and surgical outcomes for spontaneous rupture of BCLC stages A and B hepatocellular carcinoma:a case-control study[J].World J Gastroenterol,2014,20(27):9121-9127.

[5]LI M,ZHOU W,YUAN R,et al.ROCK2 promotes HCC proliferation by CEBPD inhibition through phospho-GSK3beta/beta-catenin signaling[J].FEBS Lett,2015,589(9):1018-1025.

[6]SARASWAT VA,PANDEY G,SHETTY S.Treatment algorithms for managing hepatocellular carcinoma[J].J Clin Exp Hepatol,2014,4(Suppl 3):s80-s89.

[7]QUETGLAS IM,MOEINI A,PINYOL R,et al.Integration of genomic information in the clinical management of HCC[J].Best Pract Res Clin Gastroenterol,2014,28(5):831-842.

[8]BIRCHMEIER C,BIRCHMEIER W,GHERARDI E,et al.Met,metastasis,motility and more[J].Nat Rev Mol Cell Biol,2003,4(12):915-925.

[9]GIORDANO S,COLUMBANO A.Met as a therapeutic target in HCC:facts and hopes[J].J Hepatol,2014,60(2):442-452.

[10]COOPER CS,PARK M,BLAIR DG,et al.Molecular cloning of a new transforming gene from a chemically transformed human cell line[J].Nature,1984,311(5981):29-33.

[11]WU JG,YU JW,WU HB,et al.Expressions and clinical significances of c-MET,p-MET and E2f-1 in human gastric carcinoma[J].BMC Res Notes,2014,7:6.

[12]GAO W,BING X,LI M,et al.Study of critical role of c-Met and its inhibitor SU11274 in colorectal carcinoma[J].Med Oncol,2013,30(2):546.

[13]MA PC,MAULIK G,CHRISTENSEN J,et al.C-Met:structure,functions and potential for therapeutic inhibition[J].Cancer Metastasis Rev,2003,22(4):309-325.

[14]LEE SJ,LEE J,SOHN I,et al.A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma[J].Anticancer Res,2013,33(11):5179-5186.

[15]GOYAL L,MUZUMDAR MD,ZHU AX.Targeting the HGF/c-MET pathway in hepatocellular carcinoma[J].Clin Cancer Res,2013,19(9):2310-2318.

[16]UEKI T,FUJIMOTO J,SUZUKI T,et al.Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma[J].Hepatology,1997,25(4):862-866.

[17]ZHANG SZ,PAN FY,XU JF,et al.Knockdown of c-Met by adenovirus-delivered small interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo[J].Mol Cancer Ther,2005,4(10):1577-1584.

[18]TIRAN Z,OREN A,HERMESH C,et al.A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway[J].Clin Cancer Res,2008,14(14):4612-4621.

[19]DANILKOVITCH-MIAGKOVA A,ZBAR B.Dysregulation of Met receptor tyrosine kinase activity in invasive tumors[J].J Clin Invest,2002,109(7):863-867.

[20]MENARD L,PARKER PJ,KERMORGANT S.Receptor tyrosine kinase c-Met controls the cytoskeleton from different endosomes via different pathways[J].Nat Commun,2014,5:3907.

[21]XIE B,XING R,CHEN P,et al.Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference[J].J Surg Res,2010,162(2):231-238.

[22]ABOUNADER R,LAL B,LUDDY C,et al.In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis[J].FASEB J,2002,16(1):108-110.

[23]CHU JS,GE FJ,ZHANG B,et al.Expression and prognostic value of VEGFR-2,PDGFR-beta,and c-Met in advanced hepatocellular carcinoma[J].J Exp Clin Cancer Res,2013,32:16.

[24]WANG ZL,LIANG P,DONG BW,et al.Prognostic factors and recurrence of small hepatocellular carcinoma after hepatic resection or microwave ablation:a retrospective study[J].J Gastrointest Surg,2008,12(2):327-337.

[25]LEUNG KK,HAUSE RJ,BARKINGE JL,et al.Enhanced prediction of Src homology 2(SH2)domain binding potentials using a fluorescence polarization-derived c-Met,c-Kit,Erb B,and androgen receptor interactome[J].Mol Cell Proteomics,2014,13(7):1705-1723.

[26]WANG W,XU S,YIN M,et al.Essential roles of Gab1 tyrosine phosphorylation in growth factor-mediated signaling and angiogenesis[J].Int J Cardiol,2015,181:180-184.

[27]KITADE M,FACTOR VM,ANDERSEN JB,et al.Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling[J].Genes Dev,2013,27(15):1706-1717.

[28]ELLERKAMP V,LIEBER J,NAGEL C,et al.Pharmacological inhibition of beta-catenin in hepatoblastoma cells[J].Pediatr Surg Int,2013,29(2):141-149.

[29]GAO J,INAGAKI Y,SONG P,et al.Targeting c-Met as a promising strategy for the treatment of hepatocellular carcinoma[J].Pharmacol Res,2012,65(1):23-30.

[30]SHAH MA,WAINBERG ZA,CATENACCI DV,et al.Phase II study evaluating 2 dosing schedules of oral foretinib(GSK1363089),c MET/VEGFR2 inhibitor,in patients with metastatic gastric cancer[J].PLo S One,2013,8(3):e54014.

[31]AOYAMA A,KATAYAMA R,OH-HARA T,et al.Tivantinib(ARQ 197)exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance[J].Mol Cancer Ther,2014,13(12):2978-2990.

[32]INAGAKI Y,QI F,GAO J,et al.Effect of c-Met inhibitor SU11274 on hepatocellular carcinoma cell growth[J].Biosci Trends,2011,5(2):52-56.

[33]HUYNH H,ONG R,SOO KC.Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma[J].Angiogenesis,2012,15(1):59-70.

[34]CHEN X,DING G,GAO Q,et al.A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma[J].PLo S One,2013,8(5):e63093.

施引文献

资源附件(0)

访问统计